Oramed Pharmaceuticals Inc.

NasdaqCM:ORMP Stock Report

Market Cap: US$117.9m

Oramed Pharmaceuticals Past Earnings Performance

Past criteria checks 2/6

Oramed Pharmaceuticals's earnings have been declining at an average annual rate of -12.9%, while the Pharmaceuticals industry saw earnings growing at 1.7% annually. Revenues have been declining at an average rate of 3.8% per year. Oramed Pharmaceuticals's return on equity is 3.1%, and it has net margins of 412.3%.

Key information

-12.9%

Earnings growth rate

7.4%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate-3.8%
Return on equity3.1%
Net Margin412.3%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

Aug 24
Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

May 03
Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

Dec 22
Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

Oramed: Oral Insulin For Type 2 Diabetes May Become A Reality

Sep 21

Oramed to hand Korean rights for insulin capsule

Sep 09

Oramed to report early-stage trial data for oral COVID-19 shot in 3Q

Jul 07

Is Oramed Pharmaceuticals (NASDAQ:ORMP) In A Good Position To Invest In Growth?

Jun 12
Is Oramed Pharmaceuticals (NASDAQ:ORMP) In A Good Position To Invest In Growth?

Oramed And Oral Insulin: Can This Small Company Really Do It?

Apr 14

Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

Feb 23
Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

Oramed And The Hurdles Of Developing Oral Insulin

Dec 23

Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

Nov 02
Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

Oramed: Prospects Still Remain Despite Merck-Ridgeback's Progress

Oct 04

We Think Shareholders Will Probably Be Generous With Oramed Pharmaceuticals Inc.'s (NASDAQ:ORMP) CEO Compensation

Aug 24
We Think Shareholders Will Probably Be Generous With Oramed Pharmaceuticals Inc.'s (NASDAQ:ORMP) CEO Compensation

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

Jul 21
Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

Oramed reaches 50% enrollment in late-stage oral insulin study

Jun 08

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

Apr 06
Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

The Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Is Up 110% And Shareholders Are Boasting About It

Feb 12
The Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Is Up 110% And Shareholders Are Boasting About It

Oramed Pharmaceuticals EPS beats by $0.42, revenue in-line

Jan 14

Why Oramed Pharmaceuticals' (NASDAQ:ORMP) CEO Pay Matters

Jan 08
Why Oramed Pharmaceuticals' (NASDAQ:ORMP) CEO Pay Matters

Oramed's obesity drug candidate shows decrease in glucose levels

Dec 23

We Think Oramed Pharmaceuticals (NASDAQ:ORMP) Can Afford To Drive Business Growth

Dec 04
We Think Oramed Pharmaceuticals (NASDAQ:ORMP) Can Afford To Drive Business Growth

Oramed launches late-stage NASH study with oral insulin

Dec 02

Revenue & Expenses Breakdown
Beta

How Oramed Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:ORMP Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 231689
30 Sep 232-16914
30 Jun 233-201119
31 Mar 233-301126
31 Dec 223-371628
30 Sep 223-462032
30 Jun 223-461933
31 Mar 223-401827
31 Dec 213-351327
30 Nov 213-25822
31 Aug 213-22621
31 May 213-18418
28 Feb 213-15415
31 Dec 203-22521
30 Nov 203-15414
31 Aug 203-12410
31 May 203-1149
29 Feb 203-13411
30 Nov 193-13411
31 Aug 193-14414
31 May 193-15414
28 Feb 193-15414
30 Nov 183-14414
31 Aug 182-13412
31 May 182-12412
28 Feb 182-10310
30 Nov 172-10310
31 Aug 172-10310
31 May 172-13211
28 Feb 172-13210
30 Nov 161-1128
31 Aug 161-1128
31 May 160-836
29 Feb 160-836
30 Nov 150-835
31 Aug 150-735
31 May 150-734
28 Feb 150-734
30 Nov 140-634
31 Aug 140-633
31 May 140-523
28 Feb 140-423
30 Nov 130-423
31 Aug 130-422

Quality Earnings: ORMP has a large one-off gain of $16.4M impacting its last 12 months of financial results to 31st December, 2023.

Growing Profit Margin: ORMP became profitable in the past.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ORMP has become profitable over the past 5 years, growing earnings by -12.9% per year.

Accelerating Growth: ORMP has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: ORMP has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.5%).


Return on Equity

High ROE: ORMP's Return on Equity (3.1%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.